Literature DB >> 12006960

Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.

Shirley M L Tse1, Earl D Silverman, Brian W McCrindle, Rae S M Yeung.   

Abstract

OBJECTIVES: To determine if a shorter interval between Kawasaki disease (KD) treatment with intravenous immunoglobulin (IVIG) and fever onset results in increased treatment failures, need for adjunctive therapy, or development of coronary artery lesions. STUDY
DESIGN: Patients with KD (n = 178; 89 matched pairs) diagnosed between 1987 and 1999 were included in this case-control study. All patients had fever plus at least 4 of the 5 clinical criteria for KD. Eighty-nine patients who received IVIG at day 5 or earlier were matched to patients diagnosed within 4 weeks and given IVIG at days 6 to 9 of fever. Compiled data from a detailed chart review included demographics, clinical features, fever duration, investigations, disease course, and response to therapy. Differences between matched case and control pairs were analyzed by means oft tests and McNemar tests.
RESULTS: No demographic differences were noted between the two groups. Patients treated on day 5 or less of fever had a shorter total fever duration (5.2 +/- 1.9 days vs 8.0 +/- 1.8 days, P <.0001), longer fever after IVIG treatment (1.5 +/- 1.9 days vs 0.8 +/- 1.3 days, P =.008), and less coronary artery ectasia at 1 year after KD onset (4% vs 16%, P =.02). There was no significant difference between cases and control patients in the number of patients with KD recrudescence, need for repeat courses of IVIG, need for corticosteroids, length of hospitalization, or development of coronary artery aneurysms within the first 3 months. Patients who were treated on day 5 or less of fever had higher levels of serum albumin (36 +/- 5 g/L vs 33 +/- 5 g/L, P <.01) and serum ALT (115 +/- 155 U/L vs 46 +/- 49 U/L, P <.001) as well as a lower platelet count (354 +/- 131 vs 403 +/- 166, P =.02) than did control patients during the acute phase.
CONCLUSIONS: Early treatment of KD resulted in less coronary ectasia at 1 year after KD onset but was not associated with a quicker resolution of fever, an increased number of treatment failures, an increased need for adjunctive therapy, length of hospitalization, nor development of coronary artery lesions. In children with fever and classic clinical and laboratory findings of KD, treatment with IVIG on or before 5 days of fever resulted in better coronary outcomes and decreased the total length of time of clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12006960     DOI: 10.1067/mpd.2002.122469

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  38 in total

Review 1.  Update on the treatment of Kawasaki disease in childhood.

Authors:  Robert P Sundel
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

2.  Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.

Authors:  M Miura; H Ohki; T Tsuchihashi; H Yamagishi; Y Katada; K Yamada; Y Yamashita; A Sugaya; O Komiyama; H Shiro
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

Review 3.  Pediatric vasculitis.

Authors:  Ezgi Deniz Batu; Seza Ozen
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

Review 4.  Treatment of Kawasaki disease by different doses of immunoglobulin: a meta analysis of efficacy and safety.

Authors:  Jing Chen; Bin Ma; Li-Xing Lin; Yi-Ming Xue
Journal:  Transl Pediatr       Date:  2012-10

Review 5.  Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?

Authors:  Peer Malte Aries; Bernhard Hellmich; Wolfgang Ludwig Gross
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

6.  Acute tonsillitis: an unusual presentation of Kawasaki syndrome: a case report and review of the literature.

Authors:  H R Hathursinghe; S Patel; H S Uppal; J Ray
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-11-22       Impact factor: 2.503

7.  The involvement of Fc gamma receptor gene polymorphisms in Kawasaki disease.

Authors:  M Biezeveld; J Geissler; M Merkus; I M Kuipers; J Ottenkamp; T Kuijpers
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

8.  Human lymphocyte antigen B-associated transcript 2, 3, and 5 polymorphisms and haplotypes are associated with susceptibility of Kawasaki disease and coronary artery aneurysm.

Authors:  Yao-Yuan Hsieh; Ying-Ju Lin; Chi-Chen Chang; Da-Yuan Chen; Chin-Mu Hsu; Yu-Kuo Wang; Kung-Hao Hsu; Fuu-Jen Tsai
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

9.  Incomplete, atypical kawasaki disease or evolving systemic juvenile idiopathic arthritis: a case report.

Authors:  Shakeel Shaikh; Sidra Ishaque; Taimur Saleem
Journal:  Cases J       Date:  2009-08-06

10.  Inflammatory processes in Kawasaki disease reach their peak at the sixth day of fever onset: laboratory profiles according to duration of fever.

Authors:  Kyung-Yil Lee; Ji-Whan Han; Ja-Hyun Hong; Hyung-Shin Lee; Joon-Sung Lee; Kyung-Tai Whang
Journal:  J Korean Med Sci       Date:  2004-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.